{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'A', '\"QMG responder\" is defined as a patient who shows a decrease of at least 3 points on the total QMG', 'score (compared to the corresponding TCB) for at least 4 consecutive weeks with the first of these decreases', 'occurring at the latest 1 week after last infusion of IMP of the corresponding cycle. The scoring of QMG', 'should be performed by a trained evaluator.', 'An \"early MG-ADL responder\" is defined as a patient who shows a decrease of at least 2 points on the total', 'MG-ADL score (compared to the corresponding TCB) for at least 4 consecutive weeks with the first of these', 'decreases occurring after 1 or maximum 2 infusions of IMP of the corresponding cycle. The scoring of', 'MG-ADL should be performed by a trained and certified evaluator.', 'An MG-ADL \"clinically meaningful improvement\" is defined as a decrease of at least 2 points on the total', 'MG-ADL score compared to either Study Entry Baseline (SEB) or corresponding TCB.', 'A QMG \"clinically meaningful improvement\" is defined as a decrease of at least 3 points on the total QMG', 'score compared to either SEB or corresponding TCB.', 'Methodology:', 'DESCRIPTION', 'This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 trial to evaluate the efficacy,', 'safety, tolerability, quality of life and impact on normal daily activities of ARGX-113 in patients with gMG-.', 'The trial duration is 26 weeks, which consists of:', 'a treatment part where all randomized patients will be treated with IMP, and', 'a re-treatment part where patients may be re-treated with IMP on an \"as needed basis\" during the', 'timeframe of the trial.', 'The trial will include patients on a stable standard of care (SoC) with a total MG-ADL score of > 5 points at', 'Screening and Baseline and with more than 50% of the total score attributed to non-ocular symptoms.', 'The time between Treatment Cycles is based on the duration of the treatment effect and may vary from patient', 'to patient and within each patient from cycle to cycle (patient-tailored approach).', 'SAMPLE SIZE AND STRATIFICATION', 'Approximately 150 patients will be stratified according to 3 stratification factors:', 'Japanese VS. non-Japanese patients, AChR-Ab status (seropositive vs. seronegative) and SoC (patients on non-', 'steroidal immunosuppressive drugs [NSIDs] VS. patients not on NSIDs) and randomized (1:1) within each', 'stratum to be treated with either placebo or ARGX-113, on top of their current SoC. A maximum of 20% of', 'AChR-Ab seronegative patients will be allowed in the trial.', 'Definition: Japanese patient is defined as a patient whose parents and four grandparents are Japanese, who', 'has the Japanese nationality, was born in Japan, has not lived outside of Japan for a total of > 10 years and', 'currently lives in Japan.', 'TREATMENT CYCLES AND BASELINES', 'The trial will include a Screening period (pre-randomization) of approximately 2 weeks, a first Treatment', 'Cycle and a variable number of subsequent Treatment Cycles administered on an \"as needed basis\". Each', 'Treatment Cycle consists of 9 weekly visits over a period of 8 weeks, consisting of a Treatment period of 3', 'argenx BVBA', 'Confidential', 'Page 19 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'weeks (4 weekly infusions) and a Follow-up (FU) period of 5 weeks (see Figure 1). The SEB and the (first)', 'Treatment', 'Cycle Baseline will both be set at randomization (Visit 1), whilst the Baseline of each subsequent', 'Treatment Cycle (TCnB) will be set at Visit 1 of each corresponding Treatment Cycle.', 'SCREENING AND TREATMENT', \"During the Screening period, patient's eligibility for trial participation will be evaluated.\", 'During the Treatment Cycles, eligible patients will receive, on top of their current SoC and in a blinded', 'fashion, 4 weekly infusions of either 10 mg/kg ARGX-113 or placebo at Visit 1, Visit 2, Visit 3 and Visit 4 of', 'the corresponding Treatment Cycle.', 'STANDARD of CARE (SoC)', 'Patients should be on a stable dose and frequency of SoC prior to Screening (inclusion criterion n\u00b05).', 'Permitted SoC for MG treatment under this protocol include NSIDs (e.g., azathioprine, methotrexate,', 'cyclosporine, tacrolimus, mycophenolate mofetil, and cyclophosphamide), steroids, as well as', 'acetylcholinesterase (AChE) inhibitors. In case these medications are taken for another indication than MG,', 'same conditions apply.', 'For the entire duration of the trial, a change in the type or dose/regimen of SoC (replacing, adding or', 'removing SoC, or adjustment of the SoC dose and/or frequency) is not allowed. Administration of AChE', 'inhibitors must be halted for at least 12 hours prior to performing the QMG assessment. Following this', 'requirement, this possible temporary change in dosing regimen of AChE inhibitors will not be considered as a', 'change in SoC.', 'TIME BETWEEN TREATMENT CYCLES', 'At the end of each Treatment Cycle, patients will enter a variable Inter Treatment Cycle (ITC) period during', 'which they will be treated with their SoC only. The length of the ITC period may vary from patient to patient', 'and for each patient from cycle to cycle (patient-tailored approach). The visit frequency in the ITC period is', 'every two weeks, starting 14 days ( 2 days) from the last visit of the previous Treatment Cycle.', 'RE-TREATMENT', 'Each patient will start a new Treatment Cycle with ARGX-113 or placebo when all the following criteria', 'apply:', 'The patient has completed the previous Treatment Cycle (i.e. an 8-week time period after first dosing', 'date) AND', 'The patient has a total MG-ADL score of > 5 points with more than 50% of the total score due to non-', 'ocular symptoms AND', 'The Treatment Cycle can start at the latest on Day 127 and can be completed within the timeframe of the', 'trial (26 weeks) AND', 'In case the patient was an MG-ADL responder at the previous Treatment Cycle: if he/she has lost the', 'response.', 'Loss of response is defined as a patient who no longer shows a decrease of at least 2 points on the total', 'MG-ADL score compared to the corresponding TCB.', 'However, patients may not receive re-treatment with ARGX-113 or placebo if, at the time of re-treatment,', 'patients have clinical evidence of bacterial, viral or fungal disease, or any other significant disease which', 'could confound the results of the trial or put patients at undue risk. Patients who are in need of an additional', 'treatment but who are not eligible to receive re-treatment for reasons listed here will remain in the trial to', 'receive appropriate alternative MG treatment.', 'argenx BVBA', 'Confidential', 'Page 20 of 110']\n\n###\n\n", "completion": "END"}